A versatile in vitro ELISA test for quantification and quality testing of infectious, inactivated and formulated rabies virus used in veterinary monovalent or combination vaccine.

[1]  B. Blaauboer,et al.  Replacing the NIH test for rabies vaccine potency testing: a synopsis of drivers and barriers. , 2014, Biologicals : journal of the International Association of Biological Standardization.

[2]  S. Dessain,et al.  A novel site-II directed glycoprotein estimation ELISA to aid rabies vaccine manufacture for veterinary and human use. , 2014, Vaccine.

[3]  C. Jallet,et al.  A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release. , 2013, Vaccine.

[4]  Robert H Levis,et al.  Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward. , 2012, Biologicals : journal of the International Association of Biological Standardization.

[5]  Marlies Halder,et al.  The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3Rs. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[6]  P. Cabello,et al.  Potency evaluation of rabies vaccine for human use: the impact of the reduction in the number of animals per dilution. , 2009, Journal of virological methods.

[7]  S. Roche,et al.  Structures de la glycoprotéine des rhabdovirus , 2008 .

[8]  C. Jallet,et al.  A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. , 2006, Biologicals : journal of the International Association of Biological Standardization.

[9]  D. Andrews,et al.  N-glycosylation at one rabies virus glycoprotein sequon influences N-glycan processing at a distant sequon on the same molecule. , 2005, Glycobiology.

[10]  F. Superti,et al.  Role of phospholipids in rhabdovirus attachment to CER cells , 2005, Archives of Virology.

[11]  C. Milne,et al.  Establishment of batch 4 of the Biological Reference Preparation (BRP) for rabies vaccine (inactivated) for veterinary use. , 2004, Pharmeuropa bio.

[12]  C. Jallet,et al.  Inactivated rabies vaccine control and release: use of an ELISA method. , 2003, Biologicals : journal of the International Association of Biological Standardization.

[13]  Y. Gaudin,et al.  Rabies virus glycoprotein can fold in two alternative, antigenically distinct conformations depending on membrane-anchor type. , 2002, The Journal of general virology.

[14]  S. Roche,et al.  Characterization of the equilibrium between the native and fusion-inactive conformation of rabies virus glycoprotein indicates that the fusion complex is made of several trimers. , 2002, Virology.

[15]  Y. Gaudin,et al.  Soluble ectodomain of rabies virus glycoprotein expressed in eukaryotic cells folds in a monomeric conformation that is antigenically distinct from the native state of the complete, membrane-anchored glycoprotein. , 1999, The Journal of general virology.

[16]  C. Jallet,et al.  Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? , 1999, Vaccine.

[17]  B. Kieffer,et al.  Low‐affinity nerve‐growth factor receptor (P75NTR) can serve as a receptor for rabies virus , 1998, The EMBO journal.

[18]  M. Schachner,et al.  The Neural Cell Adhesion Molecule Is a Receptor for Rabies Virus , 1998, Journal of Virology.

[19]  M. Aubert,et al.  Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. , 1998, Journal of immunological methods.

[20]  M. Gastka,et al.  Rabies virus binding to the nicotinic acetylcholine receptor alpha subunit demonstrated by virus overlay protein binding assay. , 1996, The Journal of general virology.

[21]  R. Koike,et al.  Use of ELISA for in vitro potency test of rabies vaccines for animal use. , 1996, Biologicals : journal of the International Association of Biological Standardization.

[22]  J. Lyng.  Calibration of a replacement preparation for the International Standard for Rabies Immunoglobulin. , 1994, Biologicals : journal of the International Association of Biological Standardization.

[23]  R. Ruigrok,et al.  Low-pH conformational changes of rabies virus glycoprotein and their role in membrane fusion , 1993, Journal of virology.

[24]  Y. Gaudin,et al.  Antigenicity of rabies virus glycoprotein , 1991, Journal of virology.

[25]  C. Smith,et al.  The molecular biology of rabies viruses. , 1988, Reviews of infectious diseases.

[26]  A. Flamand,et al.  Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence , 1988, Journal of virology.

[27]  P. Perrin,et al.  Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies. , 1985, Vaccine.

[28]  P. Rollin,et al.  Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein , 1985, Journal of virology.

[29]  C. Smith,et al.  Antigenic variants of CVS rabies virus with altered glycosylation sites. , 1985, Virology.

[30]  A. Kawai,et al.  Production of spikeless particles of the rabies virus under conditions of low pH. , 1981, Virology.

[31]  J. Streefkerk,et al.  Periodate or glutaraldehyde for preparing peroxidase conjugates? , 1979, Journal of immunological methods.

[32]  H. Koprowski,et al.  Antigenic properties of rabies virus components. , 1973, Journal of immunology.